Reduced Dosing Regimens for Glaucoma Treatment Methods

ChangeBridge: Patent Apps - Pharma (A61K)

Published March 26th, 2026

Detected March 26th, 2026

Summary

The USPTO has published a patent application (US20260083746A1) detailing methods for treating open-angle glaucoma by transitioning patients to a once-daily dosing regimen. The proposed treatment involves a pharmaceutical composition containing timolol, brimonidine, dorzolamide, and bimatoprost.

View original document View source feed page

What changed

This document is a USPTO patent application (US20260083746A1) for a reduced dosing regimen for glaucoma treatment. The application describes methods for treating open-angle glaucoma by administering a pharmaceutical composition containing timolol, brimonidine, dorzolamide, and bimatoprost once per day, transitioning patients from more frequent dosing schedules.

As this is a patent application, it does not impose direct regulatory obligations on pharmaceutical companies or healthcare providers. However, it signals potential future developments in glaucoma treatment that may impact product development and clinical practice guidelines. Companies involved in glaucoma therapeutics should monitor the progress of this patent application and related innovations.

Source document (simplified)

← USPTO Patent Applications

REDUCED DOSING REGIMENS FOR GLAUCOMA TREATMENT

Application US20260083746A1 Kind: A1 Mar 26, 2026

Inventors

Dennis Elias Saadeh

Abstract

Methods for treating open-angle glaucoma include transitioning a patient from a twice-per-day or more treatment regimen to a once-per-day treatment regimen. The once-per-day treatment include administering a single dose of a pharmaceutical composition including timolol or a pharmaceutically acceptable salt thereof, brimonidine or a pharmaceutically acceptable salt thereof, dorzolamide or a pharmaceutically acceptable salt thereof, and bimatoprost or a pharmaceutically acceptable salt thereof, once per day.